CVasThera develops novel therapies targeting cardiovascular and bowel pathologies, and holds an exclusive global license for two patents arising from joint research with INSERM, the École des Mines d’Albi and the GALA platform. The company’s lead candidate, CVT120165, is being developed for Crohn’s disease; safety data from a 2008 Phase I study in healthy volunteers is already available from a different indication. CVasThera plans to proceed directly to a pilot Phase II trial in Crohn’s patients in 2022. The company is led by CEO and co-founder Bruno Le Grand and is based in Toulouse, France. It intends to use the newly raised funds to support clinical-stage trials, recruit additional team members and advance pharmaceutical R&D work.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2021